Why BCAL Diagnostics (ASX:BDX) Could Change the Way Breast Cancer Survivors Are Monitored

Key Highlights

• BCAL unveils BREASTEST Monitor, a blood test designed to detect breast cancer recurrence
 • Preliminary study delivers 91% sensitivity and 95% negative predictive value
 • Targets more than 4 million breast cancer survivors in the US and over 200,000 in Australia
 • Expands BCAL from breast cancer screening into long-term patient monitoring
 • Shares surged 79.17% to $0.108 following the announcement

For many breast cancer survivors, finishing treatment is not the end of the journey. The fear of cancer returning can linger for years, often accompanied by regular scans, specialist appointments and ongoing uncertainty.

BCAL Diagnostics (ASX:BDX) is aiming to change that experience.

The Australian biotechnology company has announced the development of BREASTEST Monitor, a blood-based test designed to help detect the recurrence of breast cancer in women who have previously undergone treatment.

While still progressing through further validation studies, the early results suggest the technology could become an important new tool in a global breast cancer surveillance market forecast to reach US$4.5 billion by 2030.

Unlike traditional monitoring methods that rely heavily on mammograms, ultrasounds and MRI scans, BREASTEST Monitor uses a simple blood sample to assess the likelihood of cancer returning.

The early data has caught attention.

BCAL reported that the test demonstrated 91% sensitivity, correctly identifying 20 out of 23 confirmed recurrence cases in a held-out validation cohort. The test also delivered a 95% negative predictive value (NPV), meaning it showed a high level of accuracy in ruling out recurrence when no cancer was present.

The algorithm behind the test was developed using more than 450 clinical samples before being applied to a separate validation group of 100 samples, including 23 confirmed recurrence cases and 77 imaging-negative controls.

The significance becomes clearer when viewed against the limitations of current monitoring practices.

Breast cancer recurrence remains a major clinical challenge, occurring in up to 15% of women following initial treatment. Detecting those recurrences early can be critical, as untreated local recurrence can increase the risk of cancer spreading to other parts of the body.

Yet conventional imaging methods are far from perfect.

Studies have shown mammography can miss between 25% and 32% of recurrent breast cancers, particularly in women with dense breast tissue, surgical scarring or post-treatment tissue changes. These are precisely the patients who often require the most intensive monitoring.

For BCAL, the announcement represents more than a product update. It marks a significant evolution of the company’s business model.

Historically, BCAL has focused on breast cancer screening through its BREASTESTplus platform. BREASTEST Monitor expands the company into the ongoing management and monitoring of patients after treatment, creating what management hopes will become a broader breast cancer diagnostic ecosystem.

That shift substantially increases the potential market opportunity.

More than four million breast cancer survivors in the United States and over 200,000 survivors in Australia require ongoing monitoring throughout their lives. Capturing even a small portion of that market could create a meaningful commercial opportunity for a company currently valued at approximately $36.9 million.

The company has also been building momentum across its broader diagnostics portfolio.

Over recent months, BCAL launched an Early Detection Cancer Platform, secured a validation agreement with Sonic USA for BREASTEST V2 and progressed regulatory pathways for pancreatic cancer diagnostics. It also holds exclusive Australia and New Zealand distribution rights for several cancer detection technologies developed by US-based ClearNote Health.

Chief Executive Officer Anne-Louise Arnett described the announcement as an important milestone in the company’s evolution.

“BREASTEST Monitor is an important clinical development milestone for BCAL and extends our blood-based diagnostics platform into one of the most significant areas of unmet need in breast cancer care. The team will now work through the validation processes to advance the test.”

The human impact may be just as important as the commercial opportunity.

Shane Ryan, Executive Manager Clinical Affairs Breast Cancer, highlighted the emotional burden many survivors continue to carry long after treatment ends.

“For women who have been treated for breast cancer, fear of recurrence can remain a major burden. BREASTEST Monitor is being developed to give women and their clinicians an easier, faster and non-invasive way to help evaluate the risk of local recurrence. This is about supporting women after treatment, when reassurance, and ongoing care are critically important.”

BCAL shares climbed a whopping 79.17% to $0.108 during morning trade on 18 June, with trading volumes surging as investors responded to the potential of a new diagnostic product targeting a large and underserved patient population.

Source: MarketIndex 

There are still hurdles ahead. Additional validation studies are required, including expanding testing into women under 50 before broader regulatory approvals can be pursued.

However, the early data suggests BCAL may be developing something that could make life easier for millions of breast cancer survivors while opening a significant commercial opportunity in one of healthcare’s fastest-growing diagnostic segments.

Source: BCAL Diagnostics ASX Announcement, June 2026; Company Clinical Data; Global Breast Cancer Surveillance Market Estimates.